Table 2

Blood pressure, heart rate and lipid levels in different genotypes of the β2-adrenergic receptor polymorphisms.


n
SBP
mmHg
DBP
mmHg
HR
beats/min
n
Cholesterol
mg/dl
Triglycerides
mg/dl
n
HDL
mg/dL
LDL
mg/dL

All
429
130.5 ± 15.7
79.6 ± 9.2
76.8 ± 9.5
360
224.7 ± 39.4
171.5 ± 95.7
278
46.8 ± 14.3
146.6 ± 35.9
Codon -47










     Cys/Cys
131
130 ± 1 ± 16.3
79.8 ± 9.4
77.0 ± 9.1
112
226.0 ± 40.3
168.6 ± 76.5
93
46.0 ± 14.3
148.9 ± 32.9
     Cys/Arg
195
130.9 ± 15.6
79.6 ± 9.3
76.6 ± 8.9
163
222.5 ± 38.5
175.3 ± 102.5
123
47.3 ± 13.9
144.0 ± 38.6
     Arg/Arg
103
130.1 ± 15.1
79.4 ± 8.7
76.9 ± 11.0
85
227.6 ± 40.1
167.9 ± 105.2
62
46.9 ± 15.5
148.3 ± 35.1
P

0.878
0.942
0.924

0.594
0.789

0.796
0.578
Codon 16










     Arg/Arg
59
133.6 ± 17.2
80.9 ± 9.3
78.4 ± 9.3
53
228.2 ± 45.7
178.5 ± 114.2
39
49.7 ± 15.9
149.5 ± 34.8
     Arg/Gly
197
130.0 ± 15.9
79.8 ± 9.5
76.6 ± 9.4
158
221.4 ± 38.6
164.7 ± 92.5
123
47.0 ± 14.4
143 ± 37.2
     Gly/Gly
173
129.9 ± 14.9
79.0 ± 8.9
76.5 ± 9.7
149
227.2 ± 37.8
176.0 ± 91.8
116
45.7 ± 13.8
149.4 ± 34.9
P

0.268
0.389
0.371

0.345
0.496

0.305
0.348
Codon 27










     Gln/Gln
109
130.7 ± 14.5
80.2 ± 9.0
77.2 ± 9.2
93
222.7 ± 42.3
175.9 ± 89.4
74
44.9 ± 14.0
145.6 ± 32.9
     Gln/Glu
202
130.8 ± 15.2
79.2 ± 9.1
76.6 ± 9.2
164
225.3 ± 38.3
174.1 ± 100.9
128
47.2 ± 14.3
146.5 ± 38.2
     Glu/Glu
118
130.5 ± 15.7
79.9 ± 9.5
76.8 ± 10.2
103
224.8 ± 39.4
163.3 ± 93.0
76
48.0 ± 14.8
147.8 ± 35.2
P

0.840
0.592
0.859

0.841
0.585

0.395
0.930

Comparison of blood pressure, heart rate, lipid and lipoprotein values between the different genotypes of the β2-adrenergic receptor polymorphisms in untreated patients with OSA. Total cholesterol and triglyceride levels were available for 360 patients and lipid electrophoresis for 278 patients. There were no significant differences between the genotypes.

SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein.

Bartels et al. BMC Medicine 2007 5:1   doi:10.1186/1741-7015-5-1